The US has authorized the “immediate” resumption of the use of the vaccine by Janssen, the Belgian subsidiary of Johnson & Johnson (J&J), after its administration was practically suspended ten days ago due to cases of thrombosis in women. “We have concluded that the known and potential benefits of the vaccine outweigh its known and potential risks,” said the director of the United States Food and Drug Administration (FDA) at a press conference, adding: “We are sure that this vaccine continues to meet our standards for safety, efficacy, and quality. “
–
